- Home
- MDAI vs LGVN Comparison
MDAI vs LGVN Comparison
Compare MDAI & LGVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- LGVN
- Stock Information
- Founded
- MDAI 2013
- LGVN 2014
- Country
- MDAI United States
- LGVN United States
- Employees
- MDAI N/A
- LGVN N/A
- Industry
- MDAI Medical/Dental Instruments
- LGVN Medicinal Chemicals and Botanical Products
- Sector
- MDAI Health Care
- LGVN Health Care
- Exchange
- MDAI Nasdaq
- LGVN Nasdaq
- Market Cap
- MDAI 28.3M
- LGVN 25.2M
- IPO Year
- MDAI N/A
- LGVN 2021
- Fundamental
- Price
- MDAI $1.95
- LGVN $1.56
- Analyst Decision
- MDAI Strong Buy
- LGVN Strong Buy
- Analyst Count
- MDAI 2
- LGVN 3
- Target Price
- MDAI $4.75
- LGVN $8.67
- AVG Volume (30 Days)
- MDAI 616.5K
- LGVN 164.5K
- Earning Date
- MDAI 03-26-2025
- LGVN 02-28-2025
- Dividend Yield
- MDAI N/A
- LGVN N/A
- EPS Growth
- MDAI N/A
- LGVN N/A
- EPS
- MDAI N/A
- LGVN N/A
- Revenue
- MDAI $27,264,000.00
- LGVN $1,852,000.00
- Revenue This Year
- MDAI $61.78
- LGVN $208.32
- Revenue Next Year
- MDAI N/A
- LGVN $43.96
- P/E Ratio
- MDAI N/A
- LGVN N/A
- Revenue Growth
- MDAI 44.52
- LGVN 141.46
- 52 Week Low
- MDAI $0.82
- LGVN $0.77
- 52 Week High
- MDAI $3.25
- LGVN $6.40
- Technical
- Relative Strength Index (RSI)
- MDAI 45.75
- LGVN 45.58
- Support Level
- MDAI $1.86
- LGVN $1.53
- Resistance Level
- MDAI $2.25
- LGVN $1.71
- Average True Range (ATR)
- MDAI 0.15
- LGVN 0.13
- MACD
- MDAI -0.00
- LGVN 0.02
- Stochastic Oscillator
- MDAI 37.50
- LGVN 38.30
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.